絞り込み

16525

広告

Cardiovascular effects of sitagliptin --an anti-diabetes medicine.

著者 Zhou Y , Guo Z , Yan W , Wang W
Clin Exp Pharmacol Physiol.2018 Apr 21 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (28view , 0users)

Full Text Sources

Dipeptidyl-peptidase-4 (DPP-4) inhibitors, as the most recent available anti-diabetic agents, were generally used in clinical treatment of type 2 diabetes (T2DM). In addition to anti-diabetic effects, the five most widely used DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) also exert cardiovascular protective effects. In recent years, increasing studies suggest that sitagliptin shows pleiotropic impacts towards the cardiovascular system either with or without diabetes. In this review, we summarized the recent reports to provide an update discussion about cardiovascular protective effects of sitagliptin and the corresponding mechanisms. Sitagliptin has positive effects towards ischemic cardiovascular diseases, atherosclerosis and hypertension. These effects are mainly conducted through DPP-4 inhibitions. In addition, sitagliptin exerts anti-inflammation, anti-oxidative stress, anti-apoptosis, mediation on lipid accumulation and so on, which also contributing to its cardiovascular effects. This article is protected by copyright. All rights reserved.
PMID: 29679391 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード